Enhanced antibody half-life improves in vivo activity

Nature Biotechnology

Volumn 28, Issue 2, 2010, Pages 157-159

  Zalevsky, Jonathan ^a,c   Chamberlain, Aaron K ^a   Horton, Holly M ^a   Karki, Sher ^a   Leung, Irene W L ^a   Sproule, Thomas J ^b   Lazar, Greg A ^a   Roopenian, Derry C ^b   Desjarlais, John R ^a  

^a Xencor Inc   (United States)

^b Takeda San Diego Inc   (United States)

^c JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-TUMOR ACTIVITIES; CYNOMOLGUS MONKEYS; HALF LIVES; IN-VIVO; MOUSE MODELS; NEONATAL FC RECEPTORS; THERAPEUTIC EFFICACY; TRANSGENIC MICE;

RADIOACTIVITY;

ANTIBODIES;

BEVACIZUMAB; CETUXIMAB; FC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; COLORECTAL CANCER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; HEAD AND NECK CANCER; HUMAN; IN VIVO STUDY; KIDNEY CANCER; LUNG CANCER; MONKEY; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TRANSGENIC MOUSE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; HALF-LIFE; MACACA FASCICULARIS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

MACACA FASCICULARIS; MUS MUSCULUS;

EID: 76349123565     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1601     Document Type: Article

References (15)

1. Roopenian, D.C. & Akilesh, S. Nat. Rev. Immunol. 7, 715-725 (2007).
2. Presta, L.G. Curr. Opin. Immunol. 20, 460-470 (2008).
3. Datta-Mannan, A., Witcher, D.R., Tang, Y., Watkins, J. & Wroblewski, V.J. J. Biol. Chem. 282, 1709-1717 (2007).
4. Gurbaxani, B., Dela Cruz, L.L., Chintalacharuvu, K. & Morrison, S.L. Mol. Immunol. 43, 1462-1473 (2006).
5. Dall'Acqua, W.F., Kiener, P.A. & Wu, H. J. Biol. Chem. 281, 23514-23524 (2006).
6. Hinton, P.R. et al. J. Biol. Chem. 279, 6213-6216 (2004).
7. Hinton, P.R. et al. J. Immunol. 176, 346-356 (2006).
8. Yeung, Y.A. et al. J. Immunol. 182, 7663-7671 (2009).
9. Presta, L.G. et al. Cancer Res. 57, 4593-4599 (1997).
10. Lin, Y.S. et al. J. Pharmacol. Exp. Ther. 288, 371-378 (1999).
11. Fan, Z., Lu, Y., Wu, X. & Mendelsohn, J. J. Biol. Chem. 269, 27595-27602 (1994).
12. Lammerts van Bueren, J.J. et al. Cancer Res. 66, 7630-7638 (2006).
13. Naramura, M., Gillies, S.D., Mendelsohn, J., Reisfeld, R.A. & Mueller, B.M. Cancer Immunol. Immunother. 37, 343-349 (1993).
14. Imclone Systems, Inc Biologic License Application 125084, Erbitux (Cetuximab) (US Food and Drug Administration, Feb. 12, 2004). (http://www.accessdata.fda. gov/drugsatfda-docs/bla/2004/125084-ER BITUX-PHARMR-P2.PDF).
15. Petkova, S.B. et al. Int. Immunol. 18, 1759-1769 (2006).